The Case Comprehensive Cancer Center (Case CCC), now in its 17th year, provides leadership and oversight for basic cancer research, therapeutic and non-therapeutic cancer clinical trials, prevention, control and population research, as well as community outreach for the major affiliate institutions of Case Western Reserve University: Case School of Medicine, University Hospitals of Cleveland, and the Cleveland Clinic. Located in Cleveland and serving the 3.8 million people in Northern Ohio, members of the Cancer Center manage over 7,000 new cases per year with a high rate of clinical trial access and accrual, operating under a single protocol development and review system, data safety management plan, and a coordinated clinical trials operation. Since the last competitive renewal application, the Center has increased NCI funding by more than 53%, and more than doubled its total peer-reviewed funding. The Center also accrued 877 patients to therapeutic clinical trials in 2005. Significant institutional commitment to Center development resources, faculty recruitment, shared resources, and space assures the Center's continued success and its dynamic approach to multidisciplinary cancer research and therapeutics. The Case CCC has 9 Scientific Programs, 17 shared resources including 6 that are new, and a clinical and behavioral cancer research infrastructure that prioritizes innovative translational research and investigator-initiated clinical trials that cut across the Scientific Programs. These programs include Cancer Genetics, Cell Proliferation and Cell Death, Radiation and Cellular Stress Response, Molecular Mechanisms of Oncogenesis, GU Malignancies (new), Stem Cells and Hematologic Malignancies, Developmental Therapeutics, Cancer Prevention, Control and Population Research, and Aging-Cancer Research (new). The new Shared Resources include Imaging Research, Proteomics, Hybridoma, Transgenic &Targeting, Translational Research, and Practice-Based Research Network. Each of these new Shared Resources is fully operational, supporting the cancer research of multiple members across programs, and providing a critical platform for multidisciplinary and interdisciplinary research. This scientific organization and infrastructure furthers the mission of the Case CCC: to improve the prevention, diagnosis, and therapy of cancer through discovery, evaluation, and dissemination that together reduce cancer morbidity and mortality in Northern Ohio and the Nation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA043703-21S4
Application #
8138218
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1997-08-01
Project End
2012-03-31
Budget Start
2010-06-30
Budget End
2011-03-31
Support Year
21
Fiscal Year
2010
Total Cost
$50,000
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376
Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237
Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Liu, Xia; Taftaf, Rokana; Kawaguchi, Madoka et al. (2018) Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. Cancer Discov :
Belur Nagaraj, Anil; Joseph, Peronne; Kovalenko, Olga et al. (2018) Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. Gynecol Oncol 151:525-532
Li, Jiayang; Gresham, Kenneth S; Mamidi, Ranganath et al. (2018) Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy. Int J Cardiol 273:168-176
Enane, Francis O; Saunthararajah, Yogen; Korc, Murray (2018) Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis 9:912

Showing the most recent 10 out of 1227 publications